The clinical trial was with aXivite®, aXichem’s natural analogue capsaicin, conducted as a randomized, double-blind, clinical trial of male and female subjects at an investigational center in Northeast Ohio, US. The study was conducted to outline efficacy on the effects of phenylcapsaicin on weight loss and body composition.
“We are very pleased and excited over the significance in the results and the outcome of this clinical trial. During the eight week clinical trial 39 participants concluded a program including exercise and controlled calorie intake. These results are the proof of concept that aXichem has been waiting for and it looks promising for aXivite®’s future investigations and market success.”, says Torsten Helsing, CEO of aXichem.